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Abstract
Background/Aims—We examined associations among folate and alcohol intake, SNPs in genes
involved in one-carbon metabolism and colon cancer risk.
Methods—Colon cancer cases (294 African Americans and 349 whites) were frequency matched
to population controls (437 African Americans and 611 whites) by age, race and sex from 33 North
Carolina counties from 1996 to 2000. Folate and alcohol intakes were collected by dietary interview.
Five SNPs were genotyped using DNA from whole blood: SHMT C1420T; MTRR A66G; MTR
A2756G, and the previously-reported MTHFR C677T and MTHFR A1298C. Adjusted odds ratios
(OR) and 95% confidence intervals (CI) were calculated using logistic regression.
Results—An inverse association was observed for SHMT TT genotype as compared to CC genotype
in whites (OR=0.6, 95%CI=0.4, 1.0), but not in African Americans. Inverse associations were
observed for high folate intake in individuals carrying 0 or 1 variant allele [OR 0.2 (95%CI 0.06 –
0.8) for African Americans; OR 0.2 (95%CI 0.1– 0.6) for whites] compared to low folate intake.
Modest interactions between these SNPs and alcohol or folate intakes were observed.
Conclusions—Our results are consistent with other findings and provide needed data on these
associations among African Americans.
Keywords
Alcohol; case-control study; colon cancer; folate; polymorphism
Introduction
Low folate and high alcohol intakes are associated with an increased risk of colon cancer [1].
Folate is critical to one-carbon metabolism, acting as a coenzyme in nucleotide synthesis and
DNA methylation. Folate levels may be depleted with high alcohol intake [2]. While folate has
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generally been thought to be safe and protective against cancer, there is evidence that it can
promote the growth of preneoplastic lesions and recent work has emphasized the importance
of timing and dose of folate in the carcinogenesis process [3]. In fact, investigators of a double-
blind, randomized, placebo-controlled clinical trial of recurrent colorectal adenomas recently
reported that folic acid at 1 mg/d for six to eight years did not reduce risk of recurrent colorectal
adenoma and tended to increase the risk of advanced lesions and adenoma multiplicity [4].
Thus, investigating the mechanism of action of folate and enzymes involved in folate
metabolism is important for enhancing our understanding and improving the effectiveness of
our public health recommendations.
The folate metabolism pathway is complex and involves various enzymes that regulate DNA
synthesis and DNA methylation. Among others, 5,10-methylenetetrahydrofolate reductase
(MTHFR) is required for methylation of homocysteine to methionine [5]; serine
hydroxymethyltransferase (SHMT) catalyzes the reversible conversion of serine and
tetrahydrofolate to glycine and methylene tetrahydrofolate; methionine synthase (MTR)
supports methionine homeostasis by catalyzing the remethylation of homocysteine to
methionine in a cobalamine-dependent reaction that utilizes MTHFR as methyl donor [6]; and
methionine synthase reductase (MTRR) is responsible for keeping MTR in an active form by
maintaining adequate levels of activated cobalamin, the enzyme cofactor for MTR. Single
nucleotide polymorphisms (SNPs) in the genes that encode these enzymes may modify the
effect of folate or alcohol intake on colon cancer [7].
We previously reported associations among two polymorphisms in the MTHFR gene, folate
and alcohol intake, and colon cancer risk in the North Carolina Colon Cancer Study (NCCCS)
[8]. We genotyped SNPs in three additional genes encoding enzymes involved in folate
metabolism, MTR, MTRR and SHMT to examine individual gene effects and joint effects with
folate and alcohol intake on colon cancer risk in an ethnically diverse population. We chose
these genes because they are important in folate metabolism. Our a priori hypothesis was that
diet and genes would act synergistically such that individuals with the combination of high
folate intake or no alcohol intake and increased number of variant alleles as defined by previous
functional and epidemiologic literature would be at the lowest risk for colon cancer as compared
to individuals with low folate intake or ever alcohol intake and fewer number of variant alleles.
Materials and Methods
The NCCCS has been described in detail previously [8]. Briefly, a case-control study of colon
cancer was conducted in 33 counties in North Carolina between July 1, 1996 and June 30,
2000. Individuals with a first diagnosis of histologically confirmed invasive adenocarcinoma
of the colon between July 1, 1996 and June 30, 2000 were identified through the rapid
ascertainment system of the North Carolina Central Cancer Registry. Other case eligibility
criteria included age between 40 and 85 at the time of diagnosis, residing in the 33-county
study area in North Carolina, ability to give informed consent and be mentally competent to
complete the interview, have a North Carolina driver’s license or identification card if <age
65 (because controls <age 65 were sampled from driver’s license rosters), and permission from
their primary physician to participate in the study. Controls were frequency matched to cases
by race, sex, and by 5-year age group by sampling from two sources: 10 people younger than
age 65 from Division of Motor Vehicle record of individuals with North Carolina driver’s
license or state identification cards, and 2) people age 65 and older from a list of Medicare
eligible beneficiaries obtained from the Health Care Financing Administration. As described
previously, for cases the contact rate (contacted participants/eligible) was 78%, the cooperation
rate (interviewed/eligible) was 84% and the overall response rate (product of the contact and
cooperation rates) was 66%. For controls, the contact rate was 90%, the cooperation rate was
62% and the overall response rate was 56% [8]. 643 colon cancer cases (294 African Americans
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and 349 whites) and 1048 population-based controls (437 African Americans and 611 whites)
were enrolled in the study.
Alcohol and folate (both dietary and supplemental) intakes were assessed using an interviewer-
administered Block food frequency questionnaire that was modified slightly to include regional
and ethnic foods commonly consumed in a Southern population [9]. Dietary folate was
estimated from the folate content, amount, and frequency of consumption for folate-containing
foods on the FFQ. Participants were asked if they took supplemental folate or multivitamins
on a regular basis. Individual supplemental folate intake was estimated from the formulation
of the most common over-the-counter multivitamin supplements used in the study population
(400ug folate). Only 31 participants, or 2% cases and 2% controls, reported taking folate
supplements alone (i.e., as a single vitamin, not in a multivitamin). In summary, total folate
intake was defined as the sum of dietary and supplemental folate intake, as recommended by
the Food and Drug Administration [10].
Blood samples were obtained from 86% of cases and 83% of controls from which DNA was
extracted for genotyping. Cases and controls who provided blood samples were more likely to
be male, white, and never-smokers (p<0.01), as previously reported [8]. No other differences
between those who provided blood samples and those who did not were noted for variables
such as age, education level, income, family history of colorectal cancer, or total meat intake.
Five SNPs in four genes involved in the folate metabolism pathway were genotyped. The
genotyping assays for the MTHFR C677T (rs1801133) and A1298C (rs1801131)
polymorphisms have been described previously [11].[5] For the genotyping of MTRR A66G
(rs1801394), MTR A2756G (rs1805087) and SHMT C1420T (rs1979277), TaqMan® probes
and primers were based on the genetic sequences from the SNP500 website
(www.SNP500cancer.nci.hin.gov) and the TaqMan® assays were designed using the Applied
Biosystems’ Assays-by-DesignSM service. PCR reactions consisted of unlabeled PCR primers,
allele specific TaqMan® MGB probes (FAM™ and VIC® dye-labeled), 1x TaqMan®
Universal PCR Master Mix, No AmpErase® UNG, and 15 ng of genomic DNA. PCR reactions
were performed in a 15.0 uL reaction volume using the Hot-Start format. PCR amplification
was run on a Perkin Elmer GenAmp® 9700 thermocycler using the 9600 mode under the
following conditions: 1 cycle of 50.0° C for 2 minutes (AmpErase® UNG Activation), 1 cycle
of 95.0° C for 10 minutes (AmpliTaq Gold Activation), followed by 40 cycles of 92.0° C for
15 seconds of denaturation and appropriate annealing temperature for 1 minute.
Genomic controls obtained from the Coriell Tissue Repository (Camden, New Jersey) were
used as positive controls. Samples that did not amplify or could not be scored were repeated.
Samples that did not amplify on the second run were scored as undetermined. For quality
control, a randomly selected 10% of samples were repeated. All of the 10% repeat results were
found to be identical to the initial analysis. Hardy Weinberg Equilibrium was examined for
each SNP using a goodness of fit χ2 test to compare the observed genotype frequencies with
expected genotype frequencies based on the observed allele frequencies.
Differences between cases and controls with regard to descriptive variables and risk factors
for colon cancer were compared using a t-test for continuous variables and a chi-square test
for categorical variables. Percentages or means ± standard errors are presented. Unconditional
logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs)
using SAS statistical software version 8.0. Models presented here are adjusted for offset terms
(to account for randomized recruitment scheme and to maintain the efficiency benefits of
matching) related to the age, race and gender sampling probabilities [12] used to identify
eligible participants. Folate intake was categorized into “low” versus “high” intake using the
current US Dietary Reference Intake value (low is defined as less than 400ug, high is defined
as equal to or greater than 400ug) as the cut-off. We also examined folate intake categorized
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as a tertile variable, using the 33%-ile and 67%-ile cutpoints among control subjects only. Joint
effects with genotype did not differ using the three-level folate intake variable as compared to
the dichotomous variable, so only the dichotomous variable results are presented in this paper.
Due to the low reported consumption of alcohol in this population, alcohol intake was defined
as “drinker” or “non-drinker.”
We evaluated whether the joint effects represented departures from the additive and/or
multiplicative model, because it has been suggested that joint effects that are less than
multiplicative, but greater than additive may still be relevant, especially in terms of public
health significance [13;14]. Joint effects of genotype and folate or alcohol intake were
examined by using low folate or drinker, respectively, and the genotypes’ hypothesized highest
risk category (based on previous experimental and epidemiologic literature) as the common
referent group and calculating ORs for each combination of folate or alcohol intake and
genotype. Interaction contrast ratios (ICRs) and 95% confidence intervals were determined to
examine additive interaction using the two-level genotype variables (homozygote wildtype vs.
heterozygotes+homozygote variant) and folate or alcohol intake. ICR>0 is interpreted as
greater than additive joint effects, ICR<0 is interpreted as less than additive joint effects, and
ICR=0.0 indicates no departure from additivity. Likelihood ratio tests (LRT) were used to
determine fit of the interaction term in the model to assess multiplicative interaction.
A summary SNP variable was created summing the number of variant alleles present for each
SNP for each participant. In creating the summary SNP variable, we attempted to group the
alleles for each SNP according to a priori hypotheses about their functional effects and
subsequent effect on cancer risk. For each gene, the variant allele was defined as the less
common allele, except for MTRR 66 where previous literature suggests that the more common
allele is associated with reduced risk of colon cancer, in contrast to the other gene SNPs where
the more common allele has been associated with increased risk of colon cancer. Thus, for the
summary variable, the following definitions of variant allele applied based on functional and
epidemiologic data in the literature: MTHFR 677:T; MTHFR 1298:C; SHMT 1420:T; MTRR
66:A; and MTR 2756:G.
Results
There were 546 cases (44% African Americans) and 855 controls (38% African Americans)
with complete genotyping data. Cases were slightly younger than controls (mean age cases
63.8 ± 0.4 versus 65.9 ± 0.3 yrs in controls, p=0.0001), consumed more calories from alcohol
(p= 0.0009; mean intake for cases was 64.2 ± 8.0 kcals/d and for controls was 35.8 ± 3.0 kcals/
d), used NSAIDs less frequently (p=0.04; mean was 12.6 ± 1.2 NSAIDS used per month for
cases and 15.7 ± 0.9 NSAIDS used per month for controls) and tended to consume less folate
on average than controls (p=0.07; cases = 397+10 ug/day versus controls = 421+8 ug/day).
The test for Hardy Weinberg Equilibrium was satisfied for all SNPs among both case and
control subjects separately (p>0.10).
As shown in Table 1, white carriers of the SHMT 1420TT genotype had an OR=0.6 (95%
CI=0.4, 1.0) as compared to CC carriers, while no association was observed in African
American carriers of the TT genotype (OR=1.1, 95%CI= 0.6, 1.8 as compared to CC carriers).
No other substantial associations were observed for individual or combined genotypes and
colon cancer risk.
Table 2 shows the joint effects of diet and genotype on colon cancer risk by race. For whites,
high folate intake was associated with reduced risk of colon cancer among all genotypes for
the individual SNPs. ICRs revealed weak departure from additivity for folate and genotypes,
the only statistically significant finding was for MTRR in whites (p=0.01 for ICR; p=0.04 for
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LRT evaluating multiplicative interaction). In both African Americans and whites, the inverse
association between high folate intake and colon cancer risk was strongest in those individuals
with the least number of variant alleles (OR=0.2 and 95% CIs excluded 1.0 for both ethnic
groups comparing high folate intake to low-folate intake with 0 or 1 variant alleles), and LRTs
revealed borderline statistically significant departure from interaction on the multiplicative
scale (p=0.05 for African Americans, p=0.04 for whites). When dietary folate alone or folate
supplement use alone was examined for interaction with genotypes, conclusions did not differ
from those presented in Table 2 with the exception that the LRT p-value was no longer
significant for the MTRR A66G genotype among whites (p=0.10 for dietary folate only and
p=0.43 for supplemental folate only).
For African Americans, reduced risk of colon cancer was observed for never drinkers with the
SHMT CC genotype, and for ever drinkers with the SHMT TT genotype, although neither of
these associations was statistically significant (Table 3). The ICR>0.5 suggested greater than
additive effects (p=0.002 for ICR) and the LRT suggested greater than multiplicative
interaction (p = 0.04). There was no evidence for interaction among whites. Due to small
numbers, many of the estimates were imprecise when stratified by race.
Discussion
We examined the associations among colon cancer and SNPs in genes encoding three enzymes
involved in the folate metabolism pathway, SHMT, MTRR and MTR, based on functional
changes of these SNPs and previous reports of associations with colon cancer. With the
exception of a borderline statistically significant decreased risk of colon cancer in whites with
the SHMT TT genotype as compared to the CC genotype, we found no association between the
individual SNPs studied and colon cancer risk. In combined gene analyses, which also included
two previously reported SNPs in the MTHFR gene, the inverse association between folate
intake and colon cancer was strongest among those individuals with the least number of variant
alleles for both African Americans and whites which was contrary to our a priori hypothesis
of greatest reduced risk among those with the most number of variant alleles and high folate
intake.
Genetic polymorphisms in genes that encode key enzymes in the folate pathway, such as
MTHFR, SHMT, MTRR and MTR, may contribute to colon cancer risk. Functional
polymorphisms in these genes may alter the availability of folate for DNA synthesis and
methylation, and consequently influence susceptibility to cancer. Functional changes
associated with SNPs in these folate metabolizing genes have been reported [7], though the
data are limited for most. In one study, SHMT 1420 CC genotype carriers were found to have
reduced plasma folate, reduced red cell folate and increased plasma homocysteine compared
to TT carriers [15], though no such associations were found in another study [16]. For the MTR
2756 A>G polymorphism, decreased homocysteine levels have been found for the GG
genotype as compared to the AA genotype in some studies [17–19], but not all [20–22]. For
MTRR A66G, some studies have reported elevated homocysteine levels for carriers of the
homozygote wildtype genotype (AA) as compared to other genotypes [23;24], while others
have not [25]. More research is needed regarding the functional effects of SNPs in these genes
as related to effects on folate metabolism and subsequent folate availability.
Other epidemiologic studies have found associations between some of these individual SNPs
and colon cancer risk, though few studies have examined these in African Americans. The
MTHFR 677 TT and the 1298 CC genotypes individually are associated with reduced risk of
colon cancer in the majority of studies to date [[26] and reviewed in [7]]. Lowest risk has been
found among those with both MTHFR 677TT and 1298CC genotypes [8]. For MTRR A66G,
an increased risk of colorectal cancer was observed among Japanese with the GG genotype
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compared to AA+AG referent [27], and another study found increased risk with the GG
genotype among white subjects only [28]. Results of studies of the MTR 2756 G allele and
colon cancer or colorectal adenoma have been inconsistent [7;27–29], and recent analyses of
the Nurses Health Study and Health Professionals Follow-up Study found a nonsignificant
increased risk of colorectal cancer for variant allele carriers of this SNP [30].
We observed a modest inverse association for carriers of the homozygous SHMT C1420T
variant genotype among whites. In two prospective cohort studies of colorectal cancer, no
association was reported with the SHMT genotype [16]. The difference between our finding
and the previous finding could reflect physiological differences in the effects of folate
metabolism in the colon versus the rectum. For example, an inverse association between the
MTHFR C677T genotype has also been reported for colon, but not rectal cancer [31].
We did not observe an association among African Americans for SHMT C1420T genotype and
colon cancer. Consistent with this finding, we previously reported an inverse association for
the MTHFR 1298 CC genotype and colon cancer among whites, but no association among
African Americans [8]. Differences in folate metabolism between African Americans and
whites, other than those due to variation in the measured genes, may explain lack of an
association between SHMT and colon cancer among African Americans in our study. This
hypothesis is supported by findings from a nutritional study in a controlled environment, where
African American women had statistically significant lower folate blood and urine levels,
compared to non-Hispanic white and Hispanic women, regardless of MTHFR genotype or
folate intake [32].
There is evidence that associations between some folate-metabolizing enzyme genes and colon
cancer are observed only in the context of folate or alcohol intake [33]. We were able to examine
joint effects of folate or alcohol intake and genotype on colon cancer risk by race, but were
limited by small cell sizes when examining the interaction between these gene-diet exposures.
For example, our finding of an inverse association among African American drinkers with the
SHMT TT genotype was based on only 4 cases, and therefore highly imprecise and likely to be
spurious.
A limitation of our study was the opportunity for misclassification of dietary exposures. It is
possible that nondifferential recall of folate-containing foods biased our joint effects odds ratios
toward the null. Our study design limited the opportunity for misclassification of dietary
exposures by using a modified version of an 150-item, validated food-frequency questionnaire
that was administered in-person by trained interviewers. Slight modifications to the previously-
validated FFQ were made to include foods consumed by a Southern population [9] and these
additions were not validated. However, these modifications most likely had minimal or no
effect on assessment of folate or alcohol intakes. Vitamin supplement use was evaluated as a
source of folate intake, and we estimated the amount of folate intake from individual folate
supplements from the formulation of the most common over-the-counter multivitamin
supplements used in the study population (400ug folate). Given the small number of
participants who reported consuming individual folate supplements (2% of cases and controls),
this is unlikely to have biased our results substantially. In addition, we examined the gene-
folate interactions using only dietary sources of folate intake and in separate analyses, using
only folate supplement use, and our results did not change substantially from those presented
here.
Because many genes are involved in folate metabolism, the effect of multiple functional
polymorphisms in genes encoding for enzymes in the pathway may be expected to be stronger
than the effect of any one individual polymorphism. However, we found no strong evidence
for this in our combined analyses by summing number of variant alleles and comparing the
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highest category of variant alleles to the lowest. Other studies have examined different
combinations of folate-metabolizing enzyme genes including the methylenetetrahydrofolate
dehydrogenase (MTHFDI), glutamate carboxypeptidase II (GCPII), thymidylate syntase
(TS), and reduced folate carrier (RFC) genes [16;34;35] which were not studied here, but no
clear patterns have emerged. Koushik et al. reported associations for 24 SNPs in thirteen genes
involved in one-carbon metabolism and colorectal cancer risk, and found associations for
MTHFR C677T, MTRR Ser284Thr, MTRR Arg415Cys as well as joint effects for MTR
Asp919Gly and TCN II Pro259Arg [30]. Large populations are required to examine these gene-
gene and gene-nutrient interactions using traditional epidemiologic methods. New methods of
mathematical modeling developed for this pathway may provide insight into the effects of
modifying components of the system to inform future studies [36]. Additional studies are
needed to replicate our findings in different racial/ethnic groups and improve our ability to
predict the effects of polymorphisms within genes in one-carbon metabolism and folate status
on colon cancer risk.
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